Loading…

Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials

Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long‐term survival. In the mid‐1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5‐fluorouracil‐base...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of surgical oncology 2021-05, Vol.123 (6), p.1467-1474
Main Authors:	Essaji, Yasmin, Rocha, Flavio G.
Format:	Article
Language:	English
Subjects:	adjuvant chemoradiation adjuvant chemotherapy Cancer therapies Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - radiotherapy Carcinoma, Pancreatic Ductal - surgery Carcinoma, Pancreatic Ductal - therapy Chemoradiotherapy, Adjuvant Clinical Trials, Phase III as Topic evidence‐based medicine Humans Neoadjuvant Therapy Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - radiotherapy Pancreatic Neoplasms - surgery Pancreatic Neoplasms - therapy Randomized Controlled Trials as Topic Surgical Oncology - methods
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c3532-290eeec730b24fbdb4bef212bd108ef15235fc614462c50b2d350ccb94b6bd1c3
cites	cdi_FETCH-LOGICAL-c3532-290eeec730b24fbdb4bef212bd108ef15235fc614462c50b2d350ccb94b6bd1c3
container_end_page	1474
container_issue	6
container_start_page	1467
container_title	Journal of surgical oncology
container_volume	123
creator	Essaji, Yasmin Rocha, Flavio G.
description	Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long‐term survival. In the mid‐1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5‐fluorouracil‐based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.
doi_str_mv	10.1002/jso.26382
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2511240519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2511240519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-290eeec730b24fbdb4bef212bd108ef15235fc614462c50b2d350ccb94b6bd1c3</originalsourceid><addsrcrecordid>eNp10MtKw0AUBuBBFFurC19AAm50EXvmlmaWUrQqhQrV9TCZTGpCLnWmUbLzIXxCn8TRVBeCq3PgfPwcfoSOMVxgADIuXHNBIhqTHTTEIKJQgIh30dDfSMgmAgbowLkCAISI2D4aUBpTTDgfotnSVHmtrAvyOnCtXeValUFT66ZsVt3H2_u9qrU1ygXaL8YGKi3aF1Vvgs2TsWrdBRubq9Idor3MD3O0nSP0eH31ML0J54vZ7fRyHmrKKQmJAGOMnlBICMuSNGGJyQgmSYohNhnmhPJMR5ixiGjuUUo5aJ0IlkTeaDpCZ33u2jbPrXEbWeVOm7JUtWlaJwnHmDDgWHh6-ocWTWtr_51XICbAYh55dd4rbRvnrMnk2uaVsp3EIL_alb5d-d2utyfbxDapTPorf-r0YNyD17w03f9J8m656CM_AcI0hIo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2509704856</pqid></control><display><type>article</type><title>Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials</title><source>Wiley</source><creator>Essaji, Yasmin ; Rocha, Flavio G.</creator><creatorcontrib>Essaji, Yasmin ; Rocha, Flavio G.</creatorcontrib><description>Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long‐term survival. In the mid‐1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5‐fluorouracil‐based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.26382</identifier><identifier>PMID: 33831255</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>adjuvant chemoradiation ; adjuvant chemotherapy ; Cancer therapies ; Carcinoma, Pancreatic Ductal - drug therapy ; Carcinoma, Pancreatic Ductal - radiotherapy ; Carcinoma, Pancreatic Ductal - surgery ; Carcinoma, Pancreatic Ductal - therapy ; Chemoradiotherapy, Adjuvant ; Clinical Trials, Phase III as Topic ; evidence‐based medicine ; Humans ; Neoadjuvant Therapy ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - radiotherapy ; Pancreatic Neoplasms - surgery ; Pancreatic Neoplasms - therapy ; Randomized Controlled Trials as Topic ; Surgical Oncology - methods</subject><ispartof>Journal of surgical oncology, 2021-05, Vol.123 (6), p.1467-1474</ispartof><rights>2021 Wiley Periodicals LLC</rights><rights>2021 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-290eeec730b24fbdb4bef212bd108ef15235fc614462c50b2d350ccb94b6bd1c3</citedby><cites>FETCH-LOGICAL-c3532-290eeec730b24fbdb4bef212bd108ef15235fc614462c50b2d350ccb94b6bd1c3</cites><orcidid>0000-0001-7995-0911</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33831255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Essaji, Yasmin</creatorcontrib><creatorcontrib>Rocha, Flavio G.</creatorcontrib><title>Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials</title><title>Journal of surgical oncology</title><addtitle>J Surg Oncol</addtitle><description>Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long‐term survival. In the mid‐1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5‐fluorouracil‐based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.</description><subject>adjuvant chemoradiation</subject><subject>adjuvant chemotherapy</subject><subject>Cancer therapies</subject><subject>Carcinoma, Pancreatic Ductal - drug therapy</subject><subject>Carcinoma, Pancreatic Ductal - radiotherapy</subject><subject>Carcinoma, Pancreatic Ductal - surgery</subject><subject>Carcinoma, Pancreatic Ductal - therapy</subject><subject>Chemoradiotherapy, Adjuvant</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>evidence‐based medicine</subject><subject>Humans</subject><subject>Neoadjuvant Therapy</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - radiotherapy</subject><subject>Pancreatic Neoplasms - surgery</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Surgical Oncology - methods</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10MtKw0AUBuBBFFurC19AAm50EXvmlmaWUrQqhQrV9TCZTGpCLnWmUbLzIXxCn8TRVBeCq3PgfPwcfoSOMVxgADIuXHNBIhqTHTTEIKJQgIh30dDfSMgmAgbowLkCAISI2D4aUBpTTDgfotnSVHmtrAvyOnCtXeValUFT66ZsVt3H2_u9qrU1ygXaL8YGKi3aF1Vvgs2TsWrdBRubq9Idor3MD3O0nSP0eH31ML0J54vZ7fRyHmrKKQmJAGOMnlBICMuSNGGJyQgmSYohNhnmhPJMR5ixiGjuUUo5aJ0IlkTeaDpCZ33u2jbPrXEbWeVOm7JUtWlaJwnHmDDgWHh6-ocWTWtr_51XICbAYh55dd4rbRvnrMnk2uaVsp3EIL_alb5d-d2utyfbxDapTPorf-r0YNyD17w03f9J8m656CM_AcI0hIo</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Essaji, Yasmin</creator><creator>Rocha, Flavio G.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7995-0911</orcidid></search><sort><creationdate>20210501</creationdate><title>Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials</title><author>Essaji, Yasmin ; Rocha, Flavio G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-290eeec730b24fbdb4bef212bd108ef15235fc614462c50b2d350ccb94b6bd1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>adjuvant chemoradiation</topic><topic>adjuvant chemotherapy</topic><topic>Cancer therapies</topic><topic>Carcinoma, Pancreatic Ductal - drug therapy</topic><topic>Carcinoma, Pancreatic Ductal - radiotherapy</topic><topic>Carcinoma, Pancreatic Ductal - surgery</topic><topic>Carcinoma, Pancreatic Ductal - therapy</topic><topic>Chemoradiotherapy, Adjuvant</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>evidence‐based medicine</topic><topic>Humans</topic><topic>Neoadjuvant Therapy</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - radiotherapy</topic><topic>Pancreatic Neoplasms - surgery</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Surgical Oncology - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Essaji, Yasmin</creatorcontrib><creatorcontrib>Rocha, Flavio G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Essaji, Yasmin</au><au>Rocha, Flavio G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J Surg Oncol</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>123</volume><issue>6</issue><spage>1467</spage><epage>1474</epage><pages>1467-1474</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long‐term survival. In the mid‐1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5‐fluorouracil‐based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33831255</pmid><doi>10.1002/jso.26382</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-7995-0911</orcidid></addata></record>
fulltext	fulltext
identifier	ISSN: 0022-4790
ispartof	Journal of surgical oncology, 2021-05, Vol.123 (6), p.1467-1474
issn	0022-4790 1096-9098
language	eng
recordid	cdi_proquest_miscellaneous_2511240519
source	Wiley
subjects	adjuvant chemoradiation adjuvant chemotherapy Cancer therapies Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - radiotherapy Carcinoma, Pancreatic Ductal - surgery Carcinoma, Pancreatic Ductal - therapy Chemoradiotherapy, Adjuvant Clinical Trials, Phase III as Topic evidence‐based medicine Humans Neoadjuvant Therapy Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - radiotherapy Pancreatic Neoplasms - surgery Pancreatic Neoplasms - therapy Randomized Controlled Trials as Topic Surgical Oncology - methods
title	Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T13%3A13%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Seminars%20in%20surgical%20oncology%E2%80%94Pancreas%20cancer%20adjuvant%20therapy%20trials&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Essaji,%20Yasmin&rft.date=2021-05-01&rft.volume=123&rft.issue=6&rft.spage=1467&rft.epage=1474&rft.pages=1467-1474&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.26382&rft_dat=%3Cproquest_cross%3E2511240519%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3532-290eeec730b24fbdb4bef212bd108ef15235fc614462c50b2d350ccb94b6bd1c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2509704856&rft_id=info:pmid/33831255&rfr_iscdi=true